Have a feature idea you'd love to see implemented?
Let us know!
TSHA Taysha Gene Therapies Inc
Price (delayed)
$2.18
Market cap
$446.78M
P/E Ratio
3.46
Dividend/share
N/A
EPS
$0.63
Enterprise value
$347.21M
Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to
Highlights
Taysha Gene Therapies's EPS has surged by 124% YoY
Taysha Gene Therapies's net income has surged by 89% YoY and by 80% QoQ
Taysha Gene Therapies's revenue has decreased by 31% YoY and by 23% QoQ
The gross profit has decreased by 31% YoY and by 23% QoQ
Key stats
What are the main financial stats of TSHA
Market
Valuations
Earnings
Shares outstanding
204.94M
Market cap
$446.78M
Enterprise value
$347.21M
Price to earnings (P/E)
3.46
Price to book (P/B)
5.03
Price to sales (P/S)
58.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.02
Revenue
$9.92M
EBIT
-$21.98M
EBITDA
-$19.48M
Free cash flow
-$79.43M
Per share
Balance sheet
Liquidity
EPS
$0.63
Free cash flow per share
-$0.3
Book value per share
$0.43
Revenue per share
$0.04
TBVPS
$0.67
Total assets
$180.22M
Total liabilities
$91.42M
Debt
$60.72M
Equity
$88.8M
Working capital
$132.22M
Debt to equity
0.68
Current ratio
5.51
Quick ratio
5.46
Net debt/EBITDA
5.11
Margins
Efficiency
Dividend
EBITDA margin
-196.5%
Gross margin
100%
Net margin
-229.7%
Operating margin
-885.3%
Return on assets
-12.9%
Return on equity
-27.9%
Return on invested capital
-45.4%
Return on capital employed
-14.6%
Return on sales
-221.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TSHA stock price
How has the Taysha Gene Therapies stock price performed over time
Intraday
8.46%
1 week
-3.96%
1 month
7.92%
1 year
25.29%
YTD
23.16%
QTD
8.46%
Financial performance
How have Taysha Gene Therapies's revenue and profit performed over time
Revenue
$9.92M
Gross profit
$9.92M
Operating income
-$87.77M
Net income
-$22.77M
Gross margin
100%
Net margin
-229.7%
Taysha Gene Therapies's net income has surged by 89% YoY and by 80% QoQ
The net margin has soared by 85% YoY and by 74% from the previous quarter
TSHA's operating margin is down by 46% QoQ and by 15% YoY
Taysha Gene Therapies's revenue has decreased by 31% YoY and by 23% QoQ
Growth
What is Taysha Gene Therapies's growth rate over time
Valuation
What is Taysha Gene Therapies stock price valuation
P/E
3.46
P/B
5.03
P/S
58.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.02
Taysha Gene Therapies's EPS has surged by 124% YoY
The company's equity fell by 18% QoQ
TSHA's price to book (P/B) is 12% lower than its last 4 quarters average of 5.7
TSHA's price to sales (P/S) is 52% more than its last 4 quarters average of 38.7
Taysha Gene Therapies's revenue has decreased by 31% YoY and by 23% QoQ
Efficiency
How efficient is Taysha Gene Therapies business performance
The return on invested capital has surged by 99% year-on-year and by 95% since the previous quarter
Taysha Gene Therapies's return on assets has surged by 92% YoY and by 80% QoQ
TSHA's ROE has soared by 88% since the previous quarter
Taysha Gene Therapies's return on sales has surged by 85% YoY and by 75% QoQ
Dividends
What is TSHA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TSHA.
Financial health
How did Taysha Gene Therapies financials performed over time
The company's total assets is 97% higher than its total liabilities
TSHA's total liabilities has shrunk by 63% YoY
The company's total assets fell by 10% QoQ and by 8% YoY
The debt is 32% less than the equity
Taysha Gene Therapies's debt to equity has surged by 158% YoY and by 33% QoQ
The company's equity fell by 18% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.